IC
PSTX

Ikarian Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Ikarian Capital’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-85,837
Closed -$861K – 260
2021
Q2 		$861K Hold
85,837
– – 0.07% 166
2021
Q1 		$820K Sell
85,837
-165,000
-66% -$1.62M 0.03% 242
2020
Q4 		$2.75M Buy
250,837
+22,837
+10% +$241K 0.12% 138
2020
Q3 		$2.02M Buy
+228,000
New +$2.59M 0.15% 110

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's PSTX Position: Q3 2021 in Review

Ikarian Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2021, closing a stake of 85,837 shares — an estimated $861K sold.

Ikarian Capital first reported a position in PSTX in Q3 2020 and held it in 4 quarters. The position peaked at $2.75M in Q4 2020. 65 funds tracked by Wall St. Rank hold PSTX as of Q3 2021.

  • Ikarian Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Ikarian Capital sold 85,837 Poseida Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $861K.
  • Ikarian Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • Ikarian Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $2.75M in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.